What is Curanex Pharmaceuticals Inc's market cap?

Curanex Pharmaceuticals Inc (CURX) has a market capitalization of $7.2M and trades on NASDAQ.

Who are Curanex Pharmaceuticals Inc's competitors?

Curanex Pharmaceuticals Inc's key competitors include AbbVie, Pfizer, Eli Lilly, and others. These companies compete in similar markets and product categories.

Who does Curanex Pharmaceuticals Inc partner with?

Curanex Pharmaceuticals Inc's notable partners include Dominari Securities, LLC, Rutgers University, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, and others.

Where is Curanex Pharmaceuticals Inc headquartered?

Curanex Pharmaceuticals Inc is headquartered in United States of America. It has been publicly traded since 2025.

Curanex Pharmaceuticals (CURX) Stock Fundamentals

Curanex Pharmaceuticals is a developmental stage pharmaceutical company focused on the discovery, development, and commercialization of innovative botanical drugs for inflammatory diseases.

Market cap

$7.21M-96.5%

Earnings

Q2 2026 report

August 14, 2026

EPS-$0.03

Read the full report

Next report

Date not yet announced

Competitors

By market cap

Eli Lilly$1.06T+61.1%

AbbVie$464.58B+26.4%

Gilead Sciences$183.62B+29.9%

Pfizer$161.30B+13.2%

Madrigal Pharmaceuticals, Inc.$12.5B+31.4%

eXoZymes, Inc.$69.8M-14.2%

ABVC BioPharma, Inc.$19.0M-73.0%

CUR

Curanex Pharmaceuticals Inc$7.2M—

By revenue growth

Madrigal Pharmaceuticals, Inc.+149%

By net margin

Eli Lilly33.53%+7.6pp

Pfizer15.65%+1.6pp

AbbVie9.8%+3.3pp

Gilead Sciences-10.64%-32.5pp

Madrigal Pharmaceuticals, Inc.-25.32%+29.4pp

eXoZymes, Inc.-2,909.12%—

Profile

Curanex Pharmaceuticals is a developmental stage pharmaceutical company focused on the discovery, development, and commercialization of innovative botanical drugs for inflammatory diseases. The company leverages natural substances and traditional Chinese medicine history to address unmet medical needs in autoimmune, metabolic, and viral conditions. Its core value proposition lies in a multi-target mechanism of action that aims to provide comprehensive treatment effects with potentially favorable tolerability compared to single-target chemical compounds.

Competitive position

An early-stage entrant in the niche botanical drug space, seeking to become one of the few companies to achieve FDA approval for complex plant-derived therapies.

GeographiesUnited States, Australia, China

Customer segmentsPatients with ulcerative colitis, Patients with atopic dermatitis, Patients with metabolic disorders

Business modelR&D intensive, IP licensing, Drug development

SuppliersBotanical raw material suppliers, Contract Manufacturing Organizations (CMOs), Contract Research Organizations (CROs), Academic research institutions

CustomersSpecialty pharmacies, Hospitals, Pharmaceutical distributors, Strategic licensing partners

CountryUnited States of America

Listed2025

CEOJun Liu

SectorHealthcare

IndustryBiotechnology

Websitecuranexpharma.com

FilingsSEC EDGAR

FAQ

What is Curanex Pharmaceuticals Inc's market cap?: Curanex Pharmaceuticals Inc (CURX) has a market capitalization of $7.2M and trades on NASDAQ.
Who are Curanex Pharmaceuticals Inc's competitors?: Curanex Pharmaceuticals Inc's key competitors include AbbVie, Pfizer, Eli Lilly, and others. These companies compete in similar markets and product categories.
Who does Curanex Pharmaceuticals Inc partner with?: Curanex Pharmaceuticals Inc's notable partners include Dominari Securities, LLC, Rutgers University, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, and others.
Where is Curanex Pharmaceuticals Inc headquartered?: Curanex Pharmaceuticals Inc is headquartered in United States of America. It has been publicly traded since 2025.